Vinflunine: a novel antitubulin agent in solid malignancies

Bibliography

• JACQUESY JC, FAHY J: Cancer: superacid generation of new antitumor agents. In: Biomedical Chemistry applying chemical principles to the understanding and treatment of disease. PF Torrence (Ed.), John Wiley & Sons Inc. (2000).
   Google Scholar
• KRUCZYNSKI A, HILL BT: Vinflunine, the latest vinca alkaloid in clinical development. A review of its preclinical anticancer properties. Grit. Rev. Hematol (2001) 40(2):159–173.
   Google Scholar
• KRUCZYNSKI A, BARRET JM, ETIEVANT C et al: Antimitotic and tubulin-interacting properties of vinflunine, novel fluorinated vinca alkaloid. Biochem. Phamacol (1998) 55:635–648.
   PubMed Web of Science ®Google Scholar
• LOBERT S, INGRAM JW, HILL B et al: A comparison of thermodynamic parameters for vinorelbine and vinflunine induced tubulin self-association by sedimentation velocity. Mol. Pharmacol. (1998) 53:908–915.
   PubMed Web of Science ®Google Scholar
• NGAN V, JORDAN MA, WILSON L, HILL BT: Vinflunine and vinorelbine, novel vinca alkaloids that act by modulation of microtubule dynamic instability and treadmilling. Clin. Cancer. Res. (1999) 5:432 (Abstract 639).
   Google Scholar
• NGAN V, BELLMAN K, PANDA D et al: Novel actions of the antitumor drugs vinflunine and vinorelbine on microtubules. Cancer Res. (2000) 60:5045–5051.
   PubMed Web of Science ®Google Scholar
• •An analysis of the effects of vinflunine and vinorelbine on microtubule dynamic instability.
   Google Scholar
• HOLWELL SE, HILL B T, BIBBY M C: Anti-vascular effects of vinflunine in the mac 15a transplantable adenocarcinoma model. Br. J. Cancer (2001) 84:290–295.
   PubMed Web of Science ®Google Scholar
• BARRET J-M, ETIEVANT C, HILL BT: In vitro synergistic effects of vinflunine, a novel fluorinated vinca alkaloid, in combination with other anti-cancer drugs. Cancer Chemother. Pharmacol. (2000) 45:471–476.
   PubMed Web of Science ®Google Scholar
• ETIEVANT C, BARRET JM, CABROL Net al.: Synergistic effects of the farnesyltransferase inhibitor SCH-66336 and novel vinca alkaloids in A549 non-small cell lung cancer cells in vitro. Proc. Am. Cancer Res. (2003) 9:116 (Abstract A269).
   Google Scholar
• SIMONTHSENS C, KORST AE, DE POOTER CM et al: Vinflunine and radiation: a promising radiosensitizing combination? Proc. Am. Assoc. Cancer Res. (2004) 45:6-12 (Abstract 5606).
   Google Scholar
• KRUCZYNSKI A, COLPAERT F, TARAYRE JP et al.: Preclinical in vivo antitumour activity of vinflunine, a novel fluorinated vinca alkaloid. Cancer Chemother. Pharmacol. (1998) 41:437–447.
   PubMed Web of Science ®Google Scholar
• ••Vinflunine activity has been documentedin terms of both survival prolongation and the inhibition of tumour growth, with defmite superiority over vinorelbine being shown in each of the tumour models that were evaluated.
   Google Scholar
• KRUCZYNSKI A, RICOME C, ASTRUC J et al: Marked antitumour activity of vinflunine, a new fluorinated vinca-alkaloid, in murine and human experimental tumors. Ann. Oncol. (1998) 9(2):38.
   Google Scholar
• HILL B, FIEBIG H, WAUD WR et al.: Superior in vivo experimental antitumour activity of vinflunine, relative to vinorelbine, in a panel of human tumour xenografts. Eur. J. Cancer (1999) 35(3):512–520.
   PubMed Web of Science ®Google Scholar
• KRUCZYNSKI A, ASTRUC J, C et al.: Definite antitumour activity of vinflunine, a novel fluorinated vinca alkaloid, against human tumour xenografts. Contrib. Oncol. Basel, Karger (1999) 54:369–378.
   Google Scholar
• BONFIL RD, RUSSO DM, BINDA MM et al.: Higher antitumor activity of vinflunine than vinorelbine against an orthoptic murine model of transitional cell carcinoma of the bladder. Urol. Oncol. (2002) 7:159–166.
   PubMed Web of Science ®Google Scholar
• ETIEVANT C, BARRET JM, KRUCZYNSKI A et al: Vinflunine (20', 20'-difluoro-3',4'-dihydrovinorelbine) a novel vinca alkaloid, which participates in P-glycoprotein (Pgp)-mediated multidrug resistance in vivo and in vitro.. New Drugs (1998) 16:3–17.
   Web of Science ®Google Scholar
• ETIEVANT C, KRUCZYNSKI A, BARRET JM et al.: Markedly diminished drug resistance-inducing properties of vinflunine (20',20'-difluoro-3',4'-dihydrovinorelbine) relative to vinorelbine, identified in murine and human tumour cells in vivo and in vitro. Cancer Chemother. Pharmacol. (2001) 48(1):62–70.
   PubMed Web of Science ®Google Scholar
• FOCAN CNJ, VAN HEUGEN JC, KREUTZ F et al.: Vinflunine metabolism and disposition in cancer patients. Proc. Am. Soc. Clin. Oncol. (2002) 21:495 (Abstract).
   Google Scholar
• ZORZA G, JOHNSON P, JUDSON I et al.: A Phase I pharmacokinetic study of vinflunine given on days 1 and 8 3 weeks. Proc. Am. Soc. Clin. Oncol. (2001) 20:2070 (Abstract).
   Google Scholar
• PUOZZO C, VERMORKEN JB, J et al: A Phase I pharmacokinetic study of vinflunine given on a weekly schedule. Proc. Am. Soc. Clin. Oncol. (2001) 20:2107 (Abstract).
   Google Scholar
• BENNOUNA J, FUMOLEAU P, ARMAND JP et al: Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-mm infusion every 3 weeks in patients with advanced solid tumors. Ann. Oncol. (2003) 14:630–637.
   PubMed Web of Science ®Google Scholar
• ••A Phase I study, with an optimal 3-weekschedule based on PK data.
   Google Scholar
• DELORD JP, STUPP R, PINEL MC et al.: Phase I study of vinflunine given as a 10 minute intravenous (i.v.) infusion on a weekly schedule in patients (patients) with advanced solid tumours. Proc. Am. Soc.. (2001) 20:441 (Abstract).
   Google Scholar
• JOHNSON P, O'DONNELL A, MC et al.: Phase I study of vinflunine given as a 10-minute infusion on days 1 and 8 every 3 weeks in patients with solid malignancies. Proc. Am. Soc.. (2001) 20:2100 (Abstract 88b).
   Google Scholar
• VERMORKEN JB, STUPP R, L et al.: Phase I study of i.v. vinflunine given on a weekly schedule in previously untreated patients with advanced solid tumours. Proc. Am. Soc. Clin. Oncol. (2003) 22:221 (Abstract 887).
   Google Scholar
• BUI B, THEODORE C, CULINE S et al.: Preliminary results of a Phase II study testing intravenous (IV) vinflunine (VFL) as second line therapy in patients with advanced transitional cell cancer (TCC) of the bladder. Proc. Am. Soc. Clin. Oncol. (2003) 22:391 (Abstract 1571).
   Google Scholar
• CULINE S, THEODORE C, DESANTIS M et al.: A Phase II study testing intravenous (IV) vinflunine as second line therapy in patients with advanced transitional cell cancer (TCC) of the bladder. Eur. Oncol. (2003) 5:844 (Abstract).
   Google Scholar
• WORLD HEALTH ORGANIZATION: WHO handbook for reporting results of cancer treatment. World Health Organization publication, Geneva (1979).
   Google Scholar
• FUMOLEAU P, CAMPONE M, VOROBIOF D et al.: Phase II study of i.v. vinflunine as second line in patients with metastatic breast cancer after anthracycline- failure. Proc. Am. Soc. Clin Oncol. (2004) 23:12 (Abstract 542).
   Google Scholar
• CAMPONE M, VOROBIOF D, CORTES-FUNES H: Preliminary results of a Phase II study of intravenous vinflunine as second line therapy in patients with metastatic breast cancer after anhracycline-taxane based regimen failure. Breast Cancer Res. Treat (2003) 82(Suppl. 1S):85 (Abstract 355).
   Google Scholar
• BENNOUNA J, TAN EH, O'BRIEN M et al.: Phase II study of IV vinflunine (VFL) as second line treatment of patients (patients) with advanced non-small-cell lung cancer (NSCLC) previously treated with a platinum based regimen. Final results. Proc. Am. Soc. Clin. Oncol. (2004) 23:648 (Abstract 7139).
   Google Scholar
• TALBOT J, MARGERY G, DABUIS G et al.: Interim results of the Phase II study of vinflunine (VFL) in malignant pleural mesothelioma (MPM). Proc. Am. Soc.. (2005) (Abstract 7171).
   Google Scholar
• SOUQUET P J, RAMLAU R, SUN X et al.: Vinflunine and cisplatin combination in first line treatment of advanced non-small-cell lung cancer. Final results of a Phase II study. Proceedings of the 11th World Conference on lung cancer. Lung Cancer (2005) 49(2) (Abstract P–574).
   Google Scholar
• THERASSE P, ARBRUCK SG, E et al.: New guidelines to evaluate the response to treatment in solid tumors. J. Nati Cancer Inst. (2000) 92:205–216.
   PubMed Web of Science ®Google Scholar
• LEMARIE E, BENNOUNA J, GROSSI F et al: Vinflunine (VFL) in combination with gemcitabine (GEM) for treatment of advanced non-small cell lung cancer (NSCLC) in chemonthsnaive patients (patients): preliminary results of a Phase I and pharmacokinetic study. Proc. Am. Soc.. (2005) (Abstract 7266).
   Google Scholar
• TOURANI JM, PINEL MC, PLANCHARD D et al.: Phase land pharmacokinetic study of vinflunine (VFL) in combination with carboplatin (CBDCA) for treatment of advanced non-small cell lung cancer (NSCLC) in chemonthsnaive patients (patients): final results. Proc. Am. Soc. Clin. Oncol. (2005) (Abstract 7271).
   Google Scholar
• BARRET JM, ETIEVANT C, HILL BT: In vitro synergistic effects of vinflunine, a novel fluorinated vinca alkaloid, in combination with other anti-cancer drugs. Cancer Chemother. Pharmacol. (2000) 45:471–476.
   PubMed Web of Science ®Google Scholar
• ETIEVANT C, BARRET JM, CABROL Net al: Synergistic effects of the farnesyltransferase inhibitor SCH-66336 and novel vinca alkaloids in A549 non-small cell lung cancer cells in vitro.. Cancer Res. (2003) 9:116 (Abstract A269).
   Google Scholar
• KRUCZYNSKI A, RICOME C, J et al.: Markedly augmented in vivo experimental antitumour activity with vinflunine, the most recent vinca alkaloid to activity in Phase I clinical trials, when combined with DNA damaging anticancer agents. Proc. Am. Assoc. Cancer Res. (2002) 43:268.
   Google Scholar
• SHNYDER SD, COOPER PA, GYSELINCK N et al.: Vinflunine potentiates the activity of cisplatin but not 5-fluorouracil in transplantable murine adenocarcinoma model. Anticancer Res. (2003) 23:4815–4820.
   PubMed Web of Science ®Google Scholar